Cell Therapy for Immunomodulation in Kidney Transplantation

Phase 1/2 Active not recruiting 12 enrolled Thomas Wekerle Div. of Nephrology and Dialysis, Medical University of Vienna · collab University Hospital Regensburg · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.

Timeline

Start: 2019-08-01
Primary completion: 2024-06-30
Completion: 2028-06

Publications

Oberbauer R, Edinger M, Berlakovich G, Kalhs P, Worel N, Heinze G, Wolzt M, Lion T, Wekerle T. A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001). Front Med (Lausanne). 2021 Jan 27;7:634260. doi: 10.3389/fmed.2020.634260. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	—	—

Indications

No indication recorded.